A Case of Cutaneous Metastatic Cholangiocarcinoma on the Percutaneous Transhepatic Biliary Drainage Catheter Insertion Site
Dear Editor: Cutaneous metastasis of cholangiocellular carcinoma (CCC) is a rare occurrence and the majority of such cases develop after the placement of a percutaneous transhepatic biliary drainage (PTBD) catheter 1 . Most cases of PTBD catheter-related cutaneous metastatic CCC that have been reported in the literature to date have rarely included a dermatologic manifestation 2 . Herein, we report a case of cutaneous metastatic CCC that developed after PTBD catheter insertion. A 74-year-old male patient who had an unresectable CCC visited our dermatology clinic for evaluation of a firm, 2 cm-sized, erythematous and hyperpigmented nodule on his right abdomen. The nodule had developed on the exit site of a former indwelling PTBD catheter. The catheter had been inserted one year prior and was removed after 5 months. A percutaneous transhepatic gallbladder drainage catheter had then been inserted near the exit site of the former PTBD catheter. The nodule had appeared 6 months after the removal of the PTBD catheter and it had gradually increased in size (Fig. 1) . The patient had a medical history of malignancies associated with percutaneous indwelling catheters; therefore, we performed a skin biopsy on the nodule to determine if it was a possible skin metastasis or a hypertrophic scar.
The histopathology results identified well-developed glands composed of atypical tumor cells between the sclerotic scar tissues (Fig. 2) . Based on the clinical and histologic findings, we made a diagnosis of metastatic CCC resulting from PTBD catheter insertion. PTBD is commonly used in the treatment of malignant biliary obstruction and catheter-related cutaneous metastasis on the PTBD exit site has been only rarely reported since the 1980s 3 . Catheter-related metastasis can develop at all sites along the catheter tract, from the insertion site to the exit site 4 . Recently, Takahashi et al. 5 suggested that the incidence of cutaneous metastasis related to PTBD has been rather underestimated. They reported that catheter site metastasis may recur meta- chronously or synchronously, and the mean time interval between catheter insertion and the onset of recurrence was 14.4 months. As in this case, catheter-related skin metastasis usually occurs at the catheter insertion site and evolves rapidly. It can be difficult to differentiate between this metastasis and a hypertrophic scar. Therefore, clinicians should make careful observations and meticulously evaluate, by histopathology, any suspicious skin lesion associated with a PTBD catheter.
